Latest Breaking News On - Prnewswire kintor pharmaceutical limited - Page 1 : comparemela.com
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SUZHOU, China, July 14, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ( Fosun Pharma Development ), on the commercialisation of proxalutamide for the treatment of COVID-19 indication in India and 28 African countries (the Collaboration Regions ). Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.
According to the licensing agreement, Fosun Pharma Development will be granted exclusive rights of registration and commercialisation of proxalutamide in the Collaboration Regions. Kintor Pharmaceutical will be eligible to receive upfront payment and milestone payments up to RMB560 million (upfront and development milestone payments up to RMB110 million and commercialisation milestone p
Share this article
Share this article
SUZHOU, China, July 13, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne subjects. GT20029 is the first topical Proteolysis Targeting Chimera (PROTAC) compound globally which has entered the clinical stage. Following China Center for Drug Evaluation (CDE) s IND approval for GT20029 s clinical study in April 2021, the clinical study in the US is about to start.
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide s Phase II Clinical Trial for Androgenetic Alopecia in the US
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.